Synsam AB (publ) SYNSAM.ST
Nasdaq Stockholm · Healthcare · Medical Instruments & Supplies
58.50 SEK
−1.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Synsam
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 5,349 | 5,984 | 6,523 | 7,200 |
| EBITDA | 1,182 | 1,346 | 1,477 | 1,598 |
| Net income | 328 | 311 | 366 | 454 |
| Balance sheet | ||||
| Equity | 2,584 | 2,516 | 2,555 | 2,436 |
| Total debt | 3,439 | 3,301 | 3,464 | 3,557 |
| Cash | 444 | 582 | 420 | 600 |
| Net debt | 2,995 | 2,719 | 3,044 | 2,957 |
| Ratios and per share | ||||
| EBITDA margin | 22.1% | 22.5% | 22.6% | 22.2% |
| Profit margin | 6.1% | 5.2% | 5.6% | 6.3% |
| Return on equity | 12.7% | 12.4% | 14.3% | 18.6% |
| Earnings/share (SEK) | 2.20 | 2.10 | 2.50 | 3.18 |
| Book value/share (SEK) | 17.34 | 16.96 | 17.42 | 17.06 |
| Shares outstanding (M) | 149 | 148 | 147 | 143 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 18.4 |
| P/B | 3.4 |
| EV / EBITDA | 7.1 |
| Net debt / EBITDA | 1.9 |
| Return on equity | 18.6% |
| Profit margin | 6.3% |
| Beta 1Y | 0.60 |
| Revenue growth 1Y | +10.4% |
| Revenue CAGR 3Y | +10.4% |
| Earnings/share CAGR 3Y | +13.0% |
| ROE avg. 3Y | 15.1% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 1.80 |
| 2025 | 1.80 |
| 2024 | 1.80 |
| 2023 | 1.70 |
| 2022 | 1.70 |
Not investment advice. Figures may contain errors from the data source.